{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
icosapent ethyl
to a specific field?
Status:
Possibly Marketed Outside US
Source:
M017
(2024)
Source URL:
First approved in 2021
Source:
21 CFR 333D
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho-rac-(1-glycerol) ammonium salt (POPG-NH4) ia a phospholipid. Can be used as an emulsifier in pharmaceutical compositions. Used for lipid modification of superhydrophobic surfaces. POPG-NH4 transforms the surface into a highly hydrophilic surface only at the positions where the solution is applied.
Status:
Possibly Marketed Outside US
Source:
M017
(2024)
Source URL:
First approved in 2021
Source:
21 CFR 333D
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho-rac-(1-glycerol) ammonium salt (POPG-NH4) ia a phospholipid. Can be used as an emulsifier in pharmaceutical compositions. Used for lipid modification of superhydrophobic surfaces. POPG-NH4 transforms the surface into a highly hydrophilic surface only at the positions where the solution is applied.
Status:
Possibly Marketed Outside US
Source:
RELIVEN by Meroven Llc
(2021)
Source URL:
First approved in 2021
Source:
RELIVEN by Meroven Llc
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M019
(2020)
Source URL:
First approved in 2020
Source:
M019
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2021)
Source URL:
First approved in 2019
Source:
M020
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
2-Hexenal belongs to the aldehyde and exists in two isomeric forms: cis (Z) and greater importance form, trans (E). Trans-2-hexenal was studied as a potential antifungal compound that can inhibits Aspergillus flavus Spore Germination. The inhibition takes place by the disruption of mitochondrial energy metabolism and the induction of early apoptosis. Besides, trans-2-hexenal can be an alternative fumigation agent for controlling M. incognita on tomato crops. Botanical nematicides have recently received increasing interest because of the high risks of some traditional nematicides to human health and the environment.
Status:
Possibly Marketed Outside US
First approved in 2019
Source:
ANADA200610
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Domitor (medetomidine hydrochloride) is indicated for use in dogs: for restraint, sedation and analgesia associated with clinical examinations and procedures, minor surgery, pre-anaesthesia and as a premedicant before thiopentone-halothane general a naesthesiaand as a premedicant before general anaesthesia with propofol. In combination with butorphanol for sedation and analgesia, and as a premedicant prior to thiopentone anaesthesia. In cats: for restraint and sedation. Medetomidine is a potent and highly selective alpha2-adrenoreceptor agonist with both central and peripheral activity, and acting both presynaptically and postsynaptically. Its primary effects are sedative and analgesic resulting from its central depressant activity. It has no local anaesthetic properties. Like other compounds of its class there are secondary effects, including bradycardia. Blood pressure is increased but then returns to normal or just below. Body temperature is decreased in a dose dependent manner and intestinal motility is also reduced. The drug has been developed by Orion Pharma. It is currently approved for dogs in the United States, and distributed in the United States by Pfizer Animal Health and by Novartis Animal Health in Canada under the product name Domitor. The marketed product is a racemic mixture of two stereoisomers; dexmedetomidine is the isomer with more useful effects, and is now marketed as Dexdomitor.
Status:
Possibly Marketed Outside US
First approved in 2018
Source:
FACOL CLASSIC ONE by OASIS TRADING
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Cloperastine (INN) or cloperastin is an antitussive and antihistamine that is marketed as a cough suppressant in Japan, Hong Kong, and in some European countries. It was first introduced in 1972 in Japan, and then in Italy in 1981. The precise mechanism of action of cloperastine is not fully clear, but several different biological activities have been identified for the drug, of which include: ligand of the gamma1 receptor (Ki = 20 nM) (likely an agonist), GIRK channel blocker (described as "potent"), antihistamine (Ki = 3.8 nM for the H1 receptor), and anticholinergic. Cloperastine possesses dual activity. It also acts as a mild bronchorelaxant and has antihistaminic activity, without acting on the central nervous system or the respiratory center.
Status:
Possibly Marketed Outside US
First approved in 2018
Source:
FACOL CLASSIC ONE by OASIS TRADING
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Cloperastine (INN) or cloperastin is an antitussive and antihistamine that is marketed as a cough suppressant in Japan, Hong Kong, and in some European countries. It was first introduced in 1972 in Japan, and then in Italy in 1981. The precise mechanism of action of cloperastine is not fully clear, but several different biological activities have been identified for the drug, of which include: ligand of the gamma1 receptor (Ki = 20 nM) (likely an agonist), GIRK channel blocker (described as "potent"), antihistamine (Ki = 3.8 nM for the H1 receptor), and anticholinergic. Cloperastine possesses dual activity. It also acts as a mild bronchorelaxant and has antihistaminic activity, without acting on the central nervous system or the respiratory center.
Status:
Possibly Marketed Outside US
Source:
NADA141475
(2017)
Source URL:
First approved in 2017
Source:
NADA141475
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Rabacfosadine was approved in 2017 under the brand name Tanovea-CA1 for the treatment of canine lymphoma. In addition, this drug has demonstrated effectiveness against non-Hodgkin's lymphoma in dogs, as well as canine cutaneous T-cell lymphoma, and relapsed canine B-cell lymphoma. Rabacfosadine a prodrug, which is hydrolyzed intracellularly to the metabolites, 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cPrPMEDAP) and 9-(2-phosphonylmethoxyethyl) guanine (PMEG). PMEG is then converted to its active phosphorylated form, which is a chain-terminating inhibitor of the replicative deoxyribonucleic acid (DNA) polymerases.
Status:
Possibly Marketed Outside US
Source:
NADA141475
(2017)
Source URL:
First approved in 2017
Source:
NADA141475
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Rabacfosadine was approved in 2017 under the brand name Tanovea-CA1 for the treatment of canine lymphoma. In addition, this drug has demonstrated effectiveness against non-Hodgkin's lymphoma in dogs, as well as canine cutaneous T-cell lymphoma, and relapsed canine B-cell lymphoma. Rabacfosadine a prodrug, which is hydrolyzed intracellularly to the metabolites, 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cPrPMEDAP) and 9-(2-phosphonylmethoxyethyl) guanine (PMEG). PMEG is then converted to its active phosphorylated form, which is a chain-terminating inhibitor of the replicative deoxyribonucleic acid (DNA) polymerases.
